A significant new study identifies three critical implications for supplement consumers and regulatory bodies. First, tyrosine supplements—widely promoted for cognitive enhancement—have been linked to a one-year mortality gap in men, contradicting safety assumptions underlying current market practices. Second, the observational nature of the finding means correlation has not been established as causation, but the magnitude warrants immediate caution regarding long-term use rather than dismissal.
Third, the results highlight urgent gaps in post-market surveillance of amino acid supplements, many of which circulate with minimal long-term safety data. Health authorities should strengthen regulatory oversight and manufacturers should fund rigorous prospective studies. For individuals currently using tyrosine supplements, consultation with healthcare providers about risk-benefit profiles is essential. This research underscores the principle that widespread supplement use does not automatically equate to proven safety, particularly over extended periods.
Read the full article on GMJ Newsroom.
Was this article helpful?
